Skip to main content Accessibility help
×
Hostname: page-component-77c89778f8-m42fx Total loading time: 0 Render date: 2024-07-17T14:13:04.194Z Has data issue: false hasContentIssue false

119 - Ramelteon

Published online by Cambridge University Press:  06 October 2020

Stephen D. Silberstein
Affiliation:
Thomas Jefferson University, Philadelphia
Michael J. Marmura
Affiliation:
Thomas Jefferson University, Philadelphia
Hsiangkuo Yuan
Affiliation:
Thomas Jefferson University, Philadelphia
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

THERAPEUTICS

Brands

• Rozerem

Generic?

• No

Class

• Melatonin receptor agonist

Commonly Prescribed for

(FDA approved in bold)

Insomnia characterized by difficulties with sleep onset

• Adjunctive for bipolar disorder

• REM-associated sleep behavior disorder in patients with Parkinson's disease (PD)

• Prevention of delirium

How the Drug Works

• Selectively binds to melatonin receptors (MT1, MT2; similar affinity) in the suprachiasmatic nuclei (SCN). It increases the activity of MT1 receptors (inhibits arousal from SCN) for sleep onset and stimulates MT2 receptors (synchronizes the circadian clock to day–night cycle) for circadian phase shifting

• No affinity for GABA, dopamine, norepinephrine, acetylcholine, opiate receptors

How Long Until It Works

• Onset in less than an hour. Optimum improvement may take days

If It Works

• Continue to use at lowest required dose with appropriate monitoring

If It Doesn't Work

• Increase dose or combine with other antiinsomnia agents. Re-evaluate underlying conditions

Best Augmenting Combos for Partial Response or Treatment-Resistance

• Often depends on the comorbidity. For insomnia, may use low dose of antihistamine, TCAs, benzodiazepines, or antipsychotics

Tests

• Not available

ADVERSE EFFECTS (AEs)

How the Drug Causes AEs

• CNS depressant

Notable AEs

• Most common: dizziness, daytime somnolence, headache

• Uncommon: hallucination, abnormal thinking, behavioral change

Life-Threatening or Dangerous AEs

• Complex sleep behavior (e.g., sleep-driving)

• Worsening of depression/suicidal ideation

• Respiratory suppression (not fully studied)

Weight Gain

• Unusual

Sedation

• Problematic

What to Do About AEs

• Reduce dose or discontinue

Best Augmenting Agents to Reduce AEs

• Most AEs cannot be reduced by use of augmenting agent

DOSING AND USE

Usual Dosage Range

• 8mg

Dosage Forms

How to Dose

• Start with 8mg within 30 minutes of going to bed

Dosing Tips

• Do not take with high-fat meal, which delays its absorption

Overdose

• Dose-dependent increases in the frequency and duration of somnolence. No antidote available

Long-Term Use

• Safe for long-term use with appropriate monitoring

Type
Chapter
Information
Essential Neuropharmacology
The Prescriber's Guide
, pp. 439 - 441
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Ramelteon
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.120
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Ramelteon
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.120
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Ramelteon
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.120
Available formats
×